Welcome to LookChem.com Sign In|Join Free
  • or
trans-(1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarbonyl chloride is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

376608-70-7

Post Buying Request

376608-70-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

376608-70-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 376608-70-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,7,6,6,0 and 8 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 376608-70:
(8*3)+(7*7)+(6*6)+(5*6)+(4*0)+(3*8)+(2*7)+(1*0)=177
177 % 10 = 7
So 376608-70-7 is a valid CAS Registry Number.

376608-70-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name trans-(1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarbonyl chloride

1.2 Other means of identification

Product number -
Other names (1R,2R)-2-(3,4-difluorophenyl)-1-cyclopropanecarbonyl chloride

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:376608-70-7 SDS

376608-70-7Downstream Products

376608-70-7Relevant academic research and scientific papers

Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents

Zhang, Hao,Liu, Jun,Zhang, Luyong,Kong, Lingyi,Yao, Hequan,Sun, Hongbin

, p. 3598 - 3602 (2012/07/14)

Ticagrelor (1) is the first reversible P2Y12 receptor antagonist blocking adenine diphosphate (ADP)-induced platelet aggregation with rapid onset and offset of effects. In this study, synthesis of ticagrelor and its derivatives has been accomplished in a convergent way. The compound design was based on modifications of ticagrelor and its major metabolite (33) in order to ameliorate their pharmacokinetic properties and dosing profile. The final compounds (1a-g, 35a-g) were evaluated for their inhibitory effect on ADP-induced platelet aggregation in rats. The assay results showed that some compounds (e.g., 1b, 1d, 33, 35b, 35f) exhibited comparable potency with that of ticagrelor.

A PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CYCLOPROPYLAMINES

-

Page/Page column 31, (2008/06/13)

This invention relates to a process for the production of optically active 2-(disubstituted aryl) cyclopropylamine derivatives and optically active 2-(disubstituted aryl) cyclopropane carboxamide derivative which are useful intermediates for the preparati

Process for the preparation of cyclopropyl carboxylic acid esters and derivatives

-

, (2008/06/13)

The invention relates to a novel process for the preparation of certain cyclopropyl carboxylic acid esters and other cyclopropyl carboxylic acid derivatives; a novel process for the preparation of dimethylsulfoxonium methylide and dimethylsulfonium methylide; to the use of certain cyclopropyl carboxylic acid esters in a process for the preparation of intermediates that can be used in the synthesis of pharmaceutically active entities; and to certain intermediates provided by these processes.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 376608-70-7